Search

Displaying results 2761 - 2770 of 4234 in total
  1. Drug

    Glofitamab

    go.drugbank.com/drugs/DB16371
    ApprovedInvestigational

    many as 40% of patients will experience relapsed or refractory disease. … ,A258433] In the context of relapsed or refractory DLBCL, glofitamab provides an alternative treatment option for patients having failed other systemic therapies or for whom targeted therapies - such as

  2. Drug

    Voxilaprevir

    go.drugbank.com/drugs/DB12026
    ApprovedInvestigational

    Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as voxilaprevir. … Voxilaprevir has been available since July 2017 in a fixed dose combination product with [sofosbuvir] and [velpatasvir] as the commercially available product Vosevi.

  3. Drug

    Daclizumab

    go.drugbank.com/drugs/DB00111
    ApprovedInvestigationalWithdrawn

    On 22 April 2008, Roche Registration Limited chose to voluntarily withdraw the marketing authorization for their product Zenapax (daclizumab), as indicated for the prophylaxis of acute organ rejection … Regardless of the withdrawal of Zenapax, Biogen and Abbvie's Zinbryta (daclizumab), as indicated for the treatment of adult patients with relapsing forms of multiple sclerosis, was approved for use by

  4. Drug

    Alanine

    go.drugbank.com/drugs/DB00160
    ApprovedInvestigationalNutraceutical

    Alanine is a non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases immunity, and provides energy for muscle...

  5. Drug

    Gepotidacin

    go.drugbank.com/drugs/DB12134
    ApprovedInvestigational

    Gepotidacin is a first-in-class triazaacenaphthylene antibacterial targeting bacterial DNA gyrase and topoisomerase IV. Its target is similar to that of fluoroquinolone antibacterials - e.g. ciprofloxacin - while being structurally and p...

  6. Drug

    Ipilimumab

    go.drugbank.com/drugs/DB06186
    ApprovedInvestigational

    Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol...

  7. Drug

    Saprisartan

    go.drugbank.com/drugs/DB01347
    Experimental

    The mode of (functional) AT1 receptor antagonism has been characterized as insurmountable/noncompetitive for saprisartan.

  8. Drug

    Tosylchloramide

    go.drugbank.com/drugs/DB14708
    Investigational

    Tosylchloramide, also known as chloramine-T, is a chlorinated and deprotonated sulfonamide used as a mild disinfectant. It is not stable in the water dissolved form.

  9. Drug

    Pirfenidone

    go.drugbank.com/drugs/DB04951
    ApprovedInvestigational

    [A251365] The FDA first approved pirfenidone alongside [nintedanib] as one of the first drugs to treat IPF.[A251165]

  10. Drug

    Didesmethylrocaglamide

    go.drugbank.com/drugs/DB15496
    Experimental

    Didesmethylrocaglamide is a naturally-occurring derivative of [rocaglamide] and belongs to a class of anti-cancer phytochemicals referred to as "rocaglamides" derived from plants of the genus _Aglaia_. … [A186760] While traditionally used for their insecticidal benefits,[A186796] this class of compounds is now being studied for use as chemotherapeutic agents in the treatment of various leukemias, lymphomas